Regulatory and Safety Aspects of Cell and Gene Therapy


Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.


  • Guidelines of cell therapy
  • safety precautions

Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

October 27-28, 2025

20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research

Madrid, Spain
October 30-31, 2025

Annual Congress on CRISPR Cas9 Technology and Genetic Engineering

Rome, Italy
November 17-18, 2025

18th International Conference on Human Genomics and Genomic Medicine

Paris, France
April 29-30, 2026

9th Annual Conference on Stem Cell and Regenerative Medicine

Dubai, UAE
May 04-05, 2026

14th World Congress on Human Genetics and Genetic Diseases

Paris, France
May 25-26, 2026

20th International Conference on Regenerative Repair and Medicine

Madrid, Spain
June 08-09, 2026

9th Global Conference on Cell and Gene Therapy

Rome, Italy
June 15-16, 2026

22nd Global Summit on Stem Cell & Regenerative Medicine

Amsterdam, Netherlands
June 18-19, 2026

16th International Conference on Human Genetics and Genetic Diseases

Singapore City, Singapore
June 18-19, 2026

19th International Conference on Genomics & Pharmacogenomics

Singapore City, Singapore
September 25-26, 2025

6th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada

Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in